Development

AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

A simplified downstream process can save time and costs but requires enabling technologies.

FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Research into oncolytic viruses potentiated by stem cells shows promise for treating cancer.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.

Scaling up chromatography resins requires a thorough understanding of their intended use.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.

ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.

Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.